3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
2
Smoldering Multiple Myeloma
1
Interventions
Lenalidomide
8
Dexamethasone
6
Calcium Dobesilate
6
Melphalan
3
elotuzumab
2
dexamethasone acetate
2
dexamethasone 21-phosphate
2
daratumumab
2
auricularum
2
Peripheral Blood Stem Cell Transplantation
2
Bortezomib
2
pomalidomide
1
piperine
1
pembrolizumab
1
ixazomib
1
ibrutinib
1
Watchful Waiting
1
Urination
1
Transplantation, Autologous
1
Stem Cell Transplantation
1
Receptors, Interleukin-6
1
Observation
1
Nivolumab
1
Metformin
1
Interleukin 1 Receptor Antagonist Protein
1
In Situ Hybridization, Fluorescence
1
IPH-2101
1
Granulocyte Colony-Stimulating Factor
1
Gene Expression Profiling
1
Filgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Smoldering Multiple Myeloma
×
IPH-2101
×
Clear all
NCT01222286
2026-05-14
KIRMONO
Innate Pharma
Phase 2
Completed
30 enrolled
10 charts